Table 1.

Demographic and Clinical Characteristics of Participants

Variable			Grade of Disease
	All Patients		III		IV
	No.	%	No.	%	No.	%
Total patients	243	100	76	31	167	69
Age, years
Mean	49		44		52
SD	12		11		11
< 45	82	34	40	53	42	25
≥ 45	161	66	36	47	125	75
Male sex	165	68	51	67	114	68
Karnofsky performance status
70	11	5	4	5	7	4
80	77	32	21	28	56	34
90	124	51	43	57	81	49
100	31	13	8	11	23	14
Status of disease at study entry
Active	46	19	14	18	32	19
Stable	197	81	62	82	135	81
No. of prior treatments
1	22	9	4	5	18	11
2	76	31	25	33	51	31
3	77	32	19	25	58	35
≥ 4	68	28	28	37	40	24
No. of prior progressions
0	17	7	7	9	10	6
1	134	55	37	49	97	58
2	59	24	12	16	47	28
≥ 3	33	14	20	26	13	8
Receiving salvage therapy
Yes	212	87	67	88	145	87
No	31	13	9	12	22	13
Receiving anti-VEGF therapy
Yes	121	50	36	47	85	51
No	122	50	40	53	82	49
Receiving decadron
Unknown	2	1	2	3	0	0
Yes	70	29	17	22	53	32
No	171	70	57	75	114	68
Receiving anti-epileptic medication
Yes	183	75	59	78	124	74
No	60	25	17	22	43	26
Functional capacity (6MWD), meters
Mean	448		441		451
SD	135		137		134
Range	102-825		102-751		182-825
% below age-sex predicted
Mean	38		39		37
SD	17		19		15
Exercise behavior, MET-hrs/wk
Mean	14		16		14
SD	19		26		16

Abbreviations: SD, standard deviation; VEGF, vascular endothelial growth factor; 6MWD, 6-minute walk distance; MET, metabolic equivalent.